Aaron E. Foster

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

34h-index5.9kcitations138works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(93), Immunotherapy and Immune Responses(46), Immune Cell Function and Interaction(43), Virus-based gene therapy research(25), T-cell and B-cell Immunology(20)

Publications137 total

1085 OPB-101: a mesothelin-specific CAR T cell therapy leveraging protein design to enhance T cell proliferation and persistence for the treatment of ovarian cancer
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
UNC Libraries·2024Open Access
Abstract LB070: In vitro modeling of antigen-driven exhaustion in human CAR T cells
Cancer Research·2024
Abstract 51: OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
Cancer Research·2024
Outsmart™ IL-2/15, a Novel Cytokine Designed to Enhance ROR1-Specific CAR T Anti-Tumor Activity While Minimizing Treg Activation and Systemic Cytokine Exposure
Blood·2023
Development of a Regulated, Optimized Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin Positive Cancers
Blood·2023
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Nature Communications·2023· 77 citedOpen Access
Abstract 2734: Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Cancer Research·2023
Abstract 4091: Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Cancer Research·2023
Abstract 2735: Development of a novel, fully human anti-CD19 chimeric antigen receptor for <i>in vivo</i> delivery via CD8-targeted fusosome
Cancer Research·2023
Supplementary Figure 1 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
Supplementary Tables 1 - 2 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
Data from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
Supplementary Figure 1 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
Data from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
Supplementary Tables 1 - 2 from Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
2023Open Access
A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
Blood·2022· 2 cited
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models
Blood·2022· 1 cited
CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies
Blood·2022· 4 cited
Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice
Blood·2022
page 1 of 7Next →

Frequent Co-authors

Cliona M. Rooney(18), Malcolm K. Brenner(10), Gianpietro Dotti(10), An Lu(9), Rebekah A. Drezek(8), Helen E. Heslop(8), Barbara Savoldo(8), Adham S. Bear(7), Ann M. Leen(7), Adam Yuh Lin(6), David Gottlieb(6), David M. Spencer(6), Joao Paulo Mattos Almeida(5), Kenneth F. Bradstock(5), J. Henri Bayle(5), Mariam Khalil(4), Catherine M. Bollard(4), Juan F. Vera(4), Aruna Mahendravada(3), Joseph K. Young(3)